Cisplatin and vindesine combination chemotherapy for advanced carcinoma of the lung: A randomized trial investigating two dosage schedules

Richard J. Gralla, E. S. Casper, D. P. Kelsen, D. W. Braun, M. E. Dukeman, N. Martini, C. W. Young, R. B. Golbey

Research output: Contribution to journalArticle

308 Citations (Scopus)

Abstract

Eighty-five patients with advanced squamous carcinoma or adenocarcinoma of the lung were randomly assigned to receive vindesine with either high dose (120 mg/m 2 of body surface area) or low dose (60 mg/m 2) cisplatin. All patients had measurable disease and had not previously received chemotherapy. The response rate was similar with both treatments (43% complete and partial remission rate), but the high dose cisplatin regimen was superior to the low dose in median duration of response (12 versus 5.5 months; p = 0.05) and in median survival for responding patients (21.7 versus 10 months; p = 0.02). Myelosuppression was generally not a treatment problem; peripheral neuropathy and moderate azotemia were the major dose-limiting toxicities. With improved survival and response rates over those reported for conventional regimens, this combination of new agents supports the approach of new drug investigation in patients with lung cancer and the importance of the incorporation of active new agents into initial chemotherapy regimens.

Original languageEnglish (US)
Pages (from-to)414-420
Number of pages7
JournalAnnals of Internal Medicine
Volume95
Issue number4
StatePublished - 1981
Externally publishedYes

Fingerprint

Vindesine
Combination Drug Therapy
Cisplatin
Appointments and Schedules
Carcinoma
Lung
Azotemia
Drug Therapy
Body Surface Area
Peripheral Nervous System Diseases
Squamous Cell Carcinoma
Lung Neoplasms
Survival Rate
Survival
Therapeutics
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Gralla, R. J., Casper, E. S., Kelsen, D. P., Braun, D. W., Dukeman, M. E., Martini, N., ... Golbey, R. B. (1981). Cisplatin and vindesine combination chemotherapy for advanced carcinoma of the lung: A randomized trial investigating two dosage schedules. Annals of Internal Medicine, 95(4), 414-420.

Cisplatin and vindesine combination chemotherapy for advanced carcinoma of the lung : A randomized trial investigating two dosage schedules. / Gralla, Richard J.; Casper, E. S.; Kelsen, D. P.; Braun, D. W.; Dukeman, M. E.; Martini, N.; Young, C. W.; Golbey, R. B.

In: Annals of Internal Medicine, Vol. 95, No. 4, 1981, p. 414-420.

Research output: Contribution to journalArticle

Gralla, RJ, Casper, ES, Kelsen, DP, Braun, DW, Dukeman, ME, Martini, N, Young, CW & Golbey, RB 1981, 'Cisplatin and vindesine combination chemotherapy for advanced carcinoma of the lung: A randomized trial investigating two dosage schedules', Annals of Internal Medicine, vol. 95, no. 4, pp. 414-420.
Gralla, Richard J. ; Casper, E. S. ; Kelsen, D. P. ; Braun, D. W. ; Dukeman, M. E. ; Martini, N. ; Young, C. W. ; Golbey, R. B. / Cisplatin and vindesine combination chemotherapy for advanced carcinoma of the lung : A randomized trial investigating two dosage schedules. In: Annals of Internal Medicine. 1981 ; Vol. 95, No. 4. pp. 414-420.
@article{5fe4f9461af44e66af2b1e05399ab76d,
title = "Cisplatin and vindesine combination chemotherapy for advanced carcinoma of the lung: A randomized trial investigating two dosage schedules",
abstract = "Eighty-five patients with advanced squamous carcinoma or adenocarcinoma of the lung were randomly assigned to receive vindesine with either high dose (120 mg/m 2 of body surface area) or low dose (60 mg/m 2) cisplatin. All patients had measurable disease and had not previously received chemotherapy. The response rate was similar with both treatments (43{\%} complete and partial remission rate), but the high dose cisplatin regimen was superior to the low dose in median duration of response (12 versus 5.5 months; p = 0.05) and in median survival for responding patients (21.7 versus 10 months; p = 0.02). Myelosuppression was generally not a treatment problem; peripheral neuropathy and moderate azotemia were the major dose-limiting toxicities. With improved survival and response rates over those reported for conventional regimens, this combination of new agents supports the approach of new drug investigation in patients with lung cancer and the importance of the incorporation of active new agents into initial chemotherapy regimens.",
author = "Gralla, {Richard J.} and Casper, {E. S.} and Kelsen, {D. P.} and Braun, {D. W.} and Dukeman, {M. E.} and N. Martini and Young, {C. W.} and Golbey, {R. B.}",
year = "1981",
language = "English (US)",
volume = "95",
pages = "414--420",
journal = "Annals of Internal Medicine",
issn = "0003-4819",
publisher = "American College of Physicians",
number = "4",

}

TY - JOUR

T1 - Cisplatin and vindesine combination chemotherapy for advanced carcinoma of the lung

T2 - A randomized trial investigating two dosage schedules

AU - Gralla, Richard J.

AU - Casper, E. S.

AU - Kelsen, D. P.

AU - Braun, D. W.

AU - Dukeman, M. E.

AU - Martini, N.

AU - Young, C. W.

AU - Golbey, R. B.

PY - 1981

Y1 - 1981

N2 - Eighty-five patients with advanced squamous carcinoma or adenocarcinoma of the lung were randomly assigned to receive vindesine with either high dose (120 mg/m 2 of body surface area) or low dose (60 mg/m 2) cisplatin. All patients had measurable disease and had not previously received chemotherapy. The response rate was similar with both treatments (43% complete and partial remission rate), but the high dose cisplatin regimen was superior to the low dose in median duration of response (12 versus 5.5 months; p = 0.05) and in median survival for responding patients (21.7 versus 10 months; p = 0.02). Myelosuppression was generally not a treatment problem; peripheral neuropathy and moderate azotemia were the major dose-limiting toxicities. With improved survival and response rates over those reported for conventional regimens, this combination of new agents supports the approach of new drug investigation in patients with lung cancer and the importance of the incorporation of active new agents into initial chemotherapy regimens.

AB - Eighty-five patients with advanced squamous carcinoma or adenocarcinoma of the lung were randomly assigned to receive vindesine with either high dose (120 mg/m 2 of body surface area) or low dose (60 mg/m 2) cisplatin. All patients had measurable disease and had not previously received chemotherapy. The response rate was similar with both treatments (43% complete and partial remission rate), but the high dose cisplatin regimen was superior to the low dose in median duration of response (12 versus 5.5 months; p = 0.05) and in median survival for responding patients (21.7 versus 10 months; p = 0.02). Myelosuppression was generally not a treatment problem; peripheral neuropathy and moderate azotemia were the major dose-limiting toxicities. With improved survival and response rates over those reported for conventional regimens, this combination of new agents supports the approach of new drug investigation in patients with lung cancer and the importance of the incorporation of active new agents into initial chemotherapy regimens.

UR - http://www.scopus.com/inward/record.url?scp=0019492001&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019492001&partnerID=8YFLogxK

M3 - Article

C2 - 7025719

AN - SCOPUS:0019492001

VL - 95

SP - 414

EP - 420

JO - Annals of Internal Medicine

JF - Annals of Internal Medicine

SN - 0003-4819

IS - 4

ER -